Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
(46 intermediate revisions by 4 users not shown)
Line 10: Line 10:
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]]
 
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]]
 +
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 +
 +
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-2.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
  
 
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]]  
 
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]]  
  
−
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]  
+
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]]  
  
−
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.06.15.docx|QIBA CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening]] ''2018.06.15''
+
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1, 2017-06-26]]
  
−
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]
+
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]]
  
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
Line 25: Line 28:
 
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
 
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
  
 +
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 +
 +
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
  
−
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
+
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | QIBA CT Lung Density Profile_09.03.2019]] (Contains Conformance Checklist, Appendix B) (<font color=green>'''Public Comment Open'''</font>: August 19 - October 16, 2019)
 +
 
 +
:*[[Media:QIBA CT Lung Density Protocols-Appendix D.xlsx|QIBA CT Lung Density Protocols-Appendix D, 2019-06-26]] (<font color=green>'''Public Comment Open'''</font>: August 19 - October 16, 2019)
  
−
Please submit comments using the'''[http://tinyurl.com/QIBA-Public-Comment-Form online form]'''
+
*[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] ('''closed''' on April 5th, 2019)
  
−
*[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] (open for public comment until April 5, 2019)
+
*[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] ('''closed''' on June 3rd, 2019)
  
  
 +
'''[[Comment Resolutions]]''' are posted for '''Past Public Comments''' and '''Past Technical Confirmations''' .
  
−
'''[[Comment Resolutions]] for Past Public Comments''' will be posted.
 
  
 
==Format for Citing Profiles==
 
==Format for Citing Profiles==

Revision as of 21:13, 15 October 2019

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles


Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations .


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL

Example:

QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement


See Also

Retrieved from "https://qibawiki.rsna.org/index.php?title=Profiles&oldid=14659"